Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aspira Women's Health Inc AWH

Healthcare Medical Devices
Aspira Women's Health Inc. is engaged in the discovery, development, and commercialization of noninvasive, artificial intelligence (AI)-powered tests to aid in the diagnosis of gynecologic diseases. The Company's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus workflow is designed to assess the risk of ovarian malignancy in women planning for surgery and uses two tests, Ova1 as the primary test and Overa as a reflex for Ova1 intermediate range results. Its in-development test pipeline includes OvaMDxSM risk assessment, EndoCheck and EndoMDx, which are designed to expand its ovarian cancer portfolio and address the tremendous need for noninvasive diagnostics for endometriosis. EndoCheck is a noninvasive test designed to identify endometriomas.


NDAQ:AWH - Post by User

Aspira Women's Health Inc
<< Previous
 Bullboard Posts
User Avatar Image
(91)
•••
Post by whytestockson Apr 09, 2024 11:30am
16 Views
Post# 35979100

Aspira Women's Health Announces Anthem Blue Cross to Provide

Aspira Women's Health Announces Anthem Blue Cross to Provide
Breaking News: $AWH Aspira Women's Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in CaliforniaAUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Aspira Women&#x2019;s Health Inc. (&#x201C;Aspira&#x201D; or the &#x201C;Company&#x201D;) (Nasdaq: AWH), a bio-analytical based women&#x2019;s health company focused on the development of gynecologic disease diagnostic tools, today announced a new...AWH - Aspira Women's Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities